1. Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach

   • Afschin Gandjour
   • Dirk Müller

   Current Opinion 16 July 2014 Pages: 471 - 476

   

2. EXOGEN Ultrasound Bone Healing System for Long Bone Fractures with Non-Union or Delayed Healing: A NICE Medical Technology Guidance

   • Ailish Higgins
   • Matthew Glover
   • Joanne Lord

   Review Article Open access 25 July 2014 Pages: 477 - 484

3. E-Vita Open Plus for Treating Complex Aneurysms and Dissections of the Thoracic Aorta: A NICE Medical Technology Guidance

   • Muralikrishnan Radhakrishnan
   • Janet Peacock
   • Stephen Keevil

   Review Article Open access 24 July 2014 Pages: 485 - 495

4. What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer

   • M. Barbieri
   • H. L. A. Weatherly
   • M. Powell

   Systematic Review Open access 25 July 2014 Pages: 497 - 510

   

5. Examining the Influence of Antenatal Care Visits and Skilled Delivery on Neonatal Deaths in Ghana

   • Monica P. Lambon-Quayefio
   • Nkechi S. Owoo

   Original Research Article 17 June 2014 Pages: 511 - 522

   

6. Diagnostic Needle Arthroscopy and the Economics of Improved Diagnostic Accuracy: A Cost Analysis

   • Jeffrey D. Voigt
   • Michael Mosier
   • Bryan Huber

   Original Research Article Open access 12 July 2014 Pages: 523 - 535

   

7. The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequent to Reference Pricing: The Case of Lamotrigine in New Zealand

   • Charon Lessing
   • Toni Ashton
   • Peter Davis

   Original Research Article 09 July 2014 Pages: 537 - 546

8. Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases

   • Brian Seal
   • Sean D. Sullivan
   • Michael Eaddy

   Original Research Article Open access 09 July 2014 Pages: 547 - 557

   

9. Comment on: “Insulin Glargine in a Brazilian State: Should the Government Disinvest?”

   • Domingos A. Malerbi

   Letter to the Editor 14 August 2014 Pages: 559 - 560

10. Authors’ Reply to Dr. Malerbi: “Insulin Glargine in a Brazilian State: Should the Government Disinvest?”

    • Ana Luísa Caires de Souza
    • Francisco de Assis Acurcio
    • Leonardo Maurício Diniz

    Letter to the Editor 14 August 2014 Pages: 561 - 563

11. Comment on: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”

    • Alessandro Curto
    • Livio Garattini

    Letter to the Editor 16 August 2014 Pages: 565 - 565

12. Authors’ Reply to Curto and Garattini: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”

    • Josh J. Carlson
    • Katie Gries
    • Louis P. Garrison

    Letter to the Editor 16 August 2014 Pages: 567 - 568